Merck announced on December 13, 2024, that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended conditional approval for its Welireg oral cancer drug in two indications.
The recommendations cover Welireg as monotherapy for adults with certain tumors associated with von Hippel-Lindau (VHL) disease, and for certain adults with previously treated advanced renal cell carcinoma (RCC). The European Commission is expected to make a final decision in the first quarter of 2025.
These positive recommendations are expected to expand Welireg's market access in Europe, building on its existing approvals. Welireg sales for the first nine months of 2024 more than doubled year-earlier levels, reaching $349 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.